Biomx Inc
PHGE
查看详细走势图
1.980USD
-0.020-1.00%
交易中 （美东）报价延迟15分钟
2.79M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-1.00%
5天
+5.32%
1月
-65.74%
6月
-78.24%
今年开始到现在
-85.73%
1年
-80.83%
查看详细走势图
TradingKey Biomx Inc股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值合理，机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
Biomx Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
2
位分析师
买入
评级
165.000
目标均价
+4961.35%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Biomx Inc亮点
亮点风险
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
估值低估
公司最新PE估值-18.64，处于3年历史低位
机构减仓
最新机构持股11.81M股，环比减少24.87%
活跃度增加
近期活跃度增加，过去20天平均换手率2.96
Biomx Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Biomx Inc简介
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
公司代码PHGE
公司Biomx Inc
CEOSolomon (Jonathan Eitan)
网址https://www.biomx.com/
常见问题
Biomx Inc(PHGE)的当前股价是多少？
Biomx Inc(PHGE)的当前股价是 1.980。
Biomx Inc的股票代码是什么？
Biomx Inc的股票代码是PHGE。
Biomx Inc股票的52周最高点是多少？
Biomx Inc股票的52周最高点是22.057。
Biomx Inc股票的52周最低点是多少？
Biomx Inc股票的52周最低点是1.500。
Biomx Inc的市值是多少？
Biomx Inc的市值是2.79M。
Biomx Inc的净利润是多少？
Biomx Inc的净利润为-17.73M。
现在Biomx Inc(PHGE)的股票是买入、持有还是卖出？
根据分析师评级，Biomx Inc(PHGE)的总体评级为买入，目标价格为165.000。
Biomx Inc(PHGE)股票的每股收益（EPS TTM）是多少
Biomx Inc(PHGE)股票的每股收益（EPS TTM）是-37.042。
相关品种
